Marine natural products are potent and promising sources of drugs among other natural products of plant, animal, and microbial origin. To date, 20 drugs from marine sources are in clinical use. Most approved marine compounds are antineoplastic, but some are also used for chronic neuropathic pain, for heparin overdosage, as haptens and vaccine carriers, and for omega-3 fatty-acid supplementation in the diet. Marine drugs have diverse structural characteristics and mechanisms of action. A considerable increase in the number of marine drugs approved for clinical use has occurred in the past few decades, which may be attributed to increasing research on marine compounds in laboratories across the world. In the present manuscript, we comprehensively studied all marine drugs that have been successfully used in the clinic. Researchers and clinicians are hopeful to discover many more drugs, as a large number of marine natural compounds are being investigated in preclinical and clinical studies.
Xiangsha Liujun Pill (XSLJP) is a traditional Chinese medical complex prescription containing ten herbs and is widely used to treat gastrointestinal diseases. This study aims to investigate the mechanism of XSLJP treating gastritis. We first identified 327 targets based on 118 active components using the TCMSP, SwissTargetPrediction and STITCH databases and 180 gastritis-related targets using the DisGeNET database. Their intersection revealed that 26 common targets may play crucial roles in gastritis therapy by XSLJP. Then, we identified 12 key active components and eight hub proteins from the ‘drug-component-common target’ network. Finally, KEGG and GO enrichment analyses revealed that the therapeutic targets of XSLJP were mainly related to inflammation and cancer pathways, such as TNF, JAK/STAT and MAPK signalling pathway. This study not only provides new ideas for further exploring the specific mechanism of XSLJP treating gastritis but also offers a theoretical basis for future research on its active components.